Sudhir Agrawal to Drug Approval
This is a "connection" page, showing publications Sudhir Agrawal has written about Drug Approval.
Connection Strength
0.058
-
Lee JK, Lee HN, Agrawal S, Balsamo JA, Clerman A, Denies S, De Groot A, Fry J, Gaudenzio N, Graves AJ, Howard KE, Hwang S, Jawa V, Jin Y, Kelly-Baker L, Knowlton E, Kolenc F, Sivakumar KK, Lee JH, Li Y, Liang L, Liu D, Liu Y, Lionberger R, Luke MC, Manangeeswaran M, Mendoza M, Murphy I, Norcross M, Polli JE, Puig M, Rao Sp N, Rogers H, Schwendeman A, Siegel R, Shubow S, Smith N, Thacker SG, Tourdot S, Yang K, Zhang L, Zhang D, Smith CJ, Pang ES, Verthelyi D. Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products. AAPS J. 2026 02 12; 28(2):61.
Score: 0.058